Bone cancer and pain

Denis R Clohisy, Lauren M. MacCormick

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter describes epidemiology and mechanisms of bone cancer pain. Pain is the most common presenting symptom in patients with skeletal metastases and is directly proportional to its impact on the cancer patient’s quality of life. Two main types of cancer pain exist: ongoing pain and breakthrough pain. Osteoclasts play an essential role in cancer-induced bone loss and contribute to the etiology of bone cancer pain. Selective inhibition of osteoclasts using either bisphosphonates or the soluble decoy receptor for RANKL, osteoprotegerin (OPG), results in inhibition of cancer-induced osteolysis, cancer pain behaviors, and neurochemical markers of peripheral and central sensitization. Significant insight into understanding bone cancer pain and the development of new therapeutic strategies for bone cancer pain are due to the development of novel animal models and recent clinical trials. The chapter further explores these therapeutic strategies.

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
PublisherWiley
Pages781-787
Number of pages7
ISBN (Electronic)9781119266594
ISBN (Print)9781119266563
DOIs
StatePublished - Jan 1 2018

Fingerprint

Bone Neoplasms
Bone
Osteoclasts
Osteoprotegerin
Epidemiology
Breakthrough Pain
Central Nervous System Sensitization
Diphosphonates
Pain
Osteolysis
Animals
Cancer Pain
Neoplasms
Animal Models
Quality of Life
Clinical Trials
Neoplasm Metastasis
Therapeutics

Keywords

  • Bone cancer pain
  • Cancer-induced bone loss
  • Central sensitization
  • Neurochemical markers
  • Osteoclasts
  • Osteoprotegerin
  • Peripheral sensitization
  • Skeletal metastases
  • Therapeutic strategies

Cite this

Clohisy, D. R., & MacCormick, L. M. (2018). Bone cancer and pain. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (pp. 781-787). Wiley. https://doi.org/10.1002/9781119266594.ch101

Bone cancer and pain. / Clohisy, Denis R; MacCormick, Lauren M.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley, 2018. p. 781-787.

Research output: Chapter in Book/Report/Conference proceedingChapter

Clohisy, DR & MacCormick, LM 2018, Bone cancer and pain. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley, pp. 781-787. https://doi.org/10.1002/9781119266594.ch101
Clohisy DR, MacCormick LM. Bone cancer and pain. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley. 2018. p. 781-787 https://doi.org/10.1002/9781119266594.ch101
Clohisy, Denis R ; MacCormick, Lauren M. / Bone cancer and pain. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Wiley, 2018. pp. 781-787
@inbook{f495a7ad21344be89c9b0af0c4d504ba,
title = "Bone cancer and pain",
abstract = "This chapter describes epidemiology and mechanisms of bone cancer pain. Pain is the most common presenting symptom in patients with skeletal metastases and is directly proportional to its impact on the cancer patient’s quality of life. Two main types of cancer pain exist: ongoing pain and breakthrough pain. Osteoclasts play an essential role in cancer-induced bone loss and contribute to the etiology of bone cancer pain. Selective inhibition of osteoclasts using either bisphosphonates or the soluble decoy receptor for RANKL, osteoprotegerin (OPG), results in inhibition of cancer-induced osteolysis, cancer pain behaviors, and neurochemical markers of peripheral and central sensitization. Significant insight into understanding bone cancer pain and the development of new therapeutic strategies for bone cancer pain are due to the development of novel animal models and recent clinical trials. The chapter further explores these therapeutic strategies.",
keywords = "Bone cancer pain, Cancer-induced bone loss, Central sensitization, Neurochemical markers, Osteoclasts, Osteoprotegerin, Peripheral sensitization, Skeletal metastases, Therapeutic strategies",
author = "Clohisy, {Denis R} and MacCormick, {Lauren M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/9781119266594.ch101",
language = "English (US)",
isbn = "9781119266563",
pages = "781--787",
booktitle = "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism",
publisher = "Wiley",

}

TY - CHAP

T1 - Bone cancer and pain

AU - Clohisy, Denis R

AU - MacCormick, Lauren M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This chapter describes epidemiology and mechanisms of bone cancer pain. Pain is the most common presenting symptom in patients with skeletal metastases and is directly proportional to its impact on the cancer patient’s quality of life. Two main types of cancer pain exist: ongoing pain and breakthrough pain. Osteoclasts play an essential role in cancer-induced bone loss and contribute to the etiology of bone cancer pain. Selective inhibition of osteoclasts using either bisphosphonates or the soluble decoy receptor for RANKL, osteoprotegerin (OPG), results in inhibition of cancer-induced osteolysis, cancer pain behaviors, and neurochemical markers of peripheral and central sensitization. Significant insight into understanding bone cancer pain and the development of new therapeutic strategies for bone cancer pain are due to the development of novel animal models and recent clinical trials. The chapter further explores these therapeutic strategies.

AB - This chapter describes epidemiology and mechanisms of bone cancer pain. Pain is the most common presenting symptom in patients with skeletal metastases and is directly proportional to its impact on the cancer patient’s quality of life. Two main types of cancer pain exist: ongoing pain and breakthrough pain. Osteoclasts play an essential role in cancer-induced bone loss and contribute to the etiology of bone cancer pain. Selective inhibition of osteoclasts using either bisphosphonates or the soluble decoy receptor for RANKL, osteoprotegerin (OPG), results in inhibition of cancer-induced osteolysis, cancer pain behaviors, and neurochemical markers of peripheral and central sensitization. Significant insight into understanding bone cancer pain and the development of new therapeutic strategies for bone cancer pain are due to the development of novel animal models and recent clinical trials. The chapter further explores these therapeutic strategies.

KW - Bone cancer pain

KW - Cancer-induced bone loss

KW - Central sensitization

KW - Neurochemical markers

KW - Osteoclasts

KW - Osteoprotegerin

KW - Peripheral sensitization

KW - Skeletal metastases

KW - Therapeutic strategies

UR - http://www.scopus.com/inward/record.url?scp=85060606181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060606181&partnerID=8YFLogxK

U2 - 10.1002/9781119266594.ch101

DO - 10.1002/9781119266594.ch101

M3 - Chapter

AN - SCOPUS:85060606181

SN - 9781119266563

SP - 781

EP - 787

BT - Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

PB - Wiley

ER -